与瘤相关的巨细胞通过PKM2二分体-STAT3复杂核转位增强了PD-L1介导的膀癌的免疫逃逸
Yongbo Yu1, Ye Liang2, Fei Xie2
1Urology Department, The Affiliated Hospital of Qingdao University, China; Key Laboratory, Department of Urology and Andrology, The Affiliated Hospital of Qingdao University, Qingdao, 266003, China; Medicine College, Qingdao University, Qingdao, China; Department of Urology, Weifang People's Hospital, Weifang Medical University, Weifang, China.
Cancer letters
|May 18, 2024
概括
M2-TAMs分泌TGF-β,通过PKM2和PD-L1.1促进膀癌的免疫逃避. 阻断TGF-β和PKM2增强了抗瘤免疫力,为膀癌提供了一个新的治疗策略.
科学领域:
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
- 癌症新陈代谢 癌症新陈代谢
背景情况:
- 与瘤相关的巨细胞 (TAMs) 是瘤微环境 (TME) 的关键,与预后不佳和对免疫疗法等疗法的耐药性有关.
- 在TME中,TAMs影响免疫代谢和免疫检查点信号的确切机制尚未完全理解.
研究的目的:
- 阐明M2-TAM衍生TGF-β如何影响膀癌 (BLCA) 中的免疫代谢和PD-L1表达.
- 为了研究酸盐激酶异酶M2 (PKM2) 在TGF-β介导的免疫逃避中的作用.
- 评估针对BLCA中TGF-β/PKM2/PD-L1轴的治疗策略.
主要方法:
- 分析M2-TAMs的TGF-β分泌及其对BLCA中的糖解的影响.
- 研究TGF-β对PKM2调节的机制,包括PKM2二聚体和p-STAT3.3的核转位.
- 在BLCA模型中评估SB-431542 (TGF-β阻断剂) 和shikonin (PKM2抑制剂) 对PD-L1表达,瘤生长和抗瘤免疫的影响.
主要成果:
- 来自M2-TAM的TGF-β增加了BLCA中的糖解,并通过PKM2促进PD-L1介导的通过PKM2进行免疫逃避.
- TGF-β通过促进PKM2二聚体-STAT3复合物的核转位来增强PKM2的表达,这驱动PD-L1的表达.
- 治疗SB-431542和什科宁显著降低了PD-L1水平,抑制了BLCA的生长,并增强了抗瘤免疫反应.
结论:
- 来自M2-TAM的TGF-β通过PKM2二聚体-STAT3核转位驱动BLCA中的PD-L1介导的免疫逃避.
- 结合阻断TGF-β受体和PKM2抑制,通过对抗瘤进展和免疫抑制,为BLCA提供了一个有希望的治疗方法.
相关概念视频
Abnormal Proliferation
4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
The Tumor Microenvironment
6.6K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.6K
Interactions Between Signaling Pathways
6.3K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.3K
PI3K/mTOR/AKT Signaling Pathway
3.5K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.5K


